


FIG. 1



Product-Limit Survival Estimates
With Number of Subjects at Risk
+ Censored
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
no 14 4 2 1
yes 23 14 5 1
0
5
10
15
death
MiCK_Use no yes

FIG. 2




Product-Limit Survival Estimates
With Number of Subjects at Risk
+ Censored
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
no 14 4 1 0
yes 23 12 4 0
0.0 2.5 5.0 7.5 10.0 12.5 15.0
prog
MiCK_Use no yes

FIG. 3

Contingency Analysis of G vs P By Site of CA

Mosaic Plot



Freq: Count

Contingency Table

Site of CA	G vs P	g < p	g >= p	
	Count			
	Total %			
	Col %			
	Row %			
Breast		1	42	43
		1.33	56.00	57.33
		33.33	58.33	
		2.33	97.67	
Lung		2	30	32
		2.67	40.00	42.67
		66.67	41.67	
		6.25	93.75	
		3	72	75
		4.00	96.00	

Tests

N	DF	-LogLike	RSquare (U)
75	1	0.36499699	0.0290

Test	ChiSquare	Prob>ChiSq
Likelihood Ratio	0.730	0.3929
Pearson	0.736	0.3910


Fisher's

Exact Test	Prob	Alternative Hypothesis
Left	0.3893	Prob(G vs P=g >= p) is greater for Site of CA=Breast than Lung
Right	0.9265	Prob(G vs P=g >= p) is greater for Site of CA=Lung than Breast
2-Tail	0.5721	Prob(G vs P=g >= p) is different across Site of CA

FIG. 4

Contingency Analysis of G vs P By Site of CA

Mosaic Plot



Freq: Count

Contingency Table

		G vs P		
	Count	g < p	g >= p	
	Total %			
	Col %			
	Row %			
Site of CA	Breast	1	42	43
		2.00	84.00	86.00
		33.33	89.36	
		2.33	97.67	
	Colon	2	5	7
		4.00	10.00	14.00
		66.67	10.64	
		28.57	71.43	
		3	47	50
		6.00	94.00	

Tests

N	DF	-LogLike	RSquare (U)
50	1	2.4110080	0.2125


Test	ChiSquare	Prob>ChiSq
Likelihood Ratio	4.822	0.0281*
Pearson	7.353	0.0067*

Fisher's Exact Test	Prob	Alternative Hypothesis
Left	0.0479*	Prob(G vs P=g >= p) is greater for Site of CA=Breast than Colon
Right	0.9962	Prob(G vs P=g >= p) is greater for Site of CA=Colon than Breast
2-Tail	0.0479*	Prob(G vs P=g >= p) is different across Site of CA

FIG. 5

Contingency Analysis of G vs P By Site of CA

Mosaic Plot



Freq: Count

Contingency Table

Site of CA	G vs P	g < p	g >= p	
	Count			
	Total %			
	Col %			
	Row %			
Breast		1	42	43
		1.22	51.22	52.44
		20.00	54.55	
		2.33	97.67	
Colon+Lung		4	35	39
		4.88	42.68	47.56
		80.00	45.45	
		10.26	89.74	
		5	77	82
		6.10	93.90	

Tests

N	DF	-LogLike	RSquare (U)
82	1	1.1847456	0.0629

Test	ChiSquare	Prob>ChiSq
Likelihood Ratio	2.369	0.1237
Pearson	2.247	0.1339

Fisher's

Exact Test	Prob	Alternative Hypothesis
Left	0.1507	Prob(G vs P=g >= p) is greater for Site of CA=Breast than Colon+Lung
Right	0.9789	Prob(G vs P=g >= p) is greater for Site of CA=Colon+Lung than Breast
2-Tail	0.1660	Prob(G vs P=g >= p) is different across Site of CA

FIG. 6



Best Generic
14
12
10
8
6
4
2
0
Colon
Lung
Site
Best Proprietary
7
6
5
4
3
2
1
0
-1
Colon
Lung
Site

FIG. 7




FIG. 8





FIG. 9



Legend: ND: data not displayed NS: not sensitive

Cisplatin	10.0	Doxorubicin	3.5	Dexil	1.2
4HC(cytoxan)	8.4	Daunorubicin	3.1	Bleomycin	1.1
Sunitinib	7.9	Vinorelbine	3.1	Vincristine	0.9
Oxaliplatin	6.7	Irinotecan	2.8	CCNU	0.8
Carboplatin	6.0	4HI(ifosfamide)	2.8	Etoposide	0.8
Melphalan	5.3	Taxotere	2.3	Gemcitabine	0.8
Vidaza	4.3	Taxol	1.8	Methotrexate	0.8
Dactinomycin	4.0	Temozolomide	1.5	Tarceva	0.7
Velcade	3.9	Gleevec(imatinib)	1.5	Alimta	0.6
Sorafenib	3.9	Procarbazine	1.3	Dacarbazine	0.6
Epirubicin	3.8	Vinblastine	1.2	5-Fluorouracil	0.3

4Hifosfamide)+Epirubicin	3.2	Gemcitabine+Taxotere	2.4
4Hifosfamide)+Doxorubicin+Dacarbazine	2.5	Methotrexate+Vinblastine	2.2

FIG. 10